Now came the hard part. Elena recruited 200 volunteers in a region with active Phoenix transmission. Half got AVI-7, half got placebo, double-blinded (neither patient nor doctor knew who got what). After 14 days, 18 people on placebo had confirmed Phoenix infections. In the AVI-7 group: just 3 infections, all mild. The drug showed 83 percent protection. But the real test was yet to come.
The results, when unblinded, stunned the medical community. Among high-risk patients (elderly, asthmatics, pregnant women), AVI-7 reduced hospitalization rates by 76 percent compared to placebo. Even more remarkable, viral sequencing showed zero resistance mutations after 60 days of treatment—something never seen with oseltamivir (Tamiflu). anti virus trial
Elena’s team had spent three years developing a broad-spectrum antiviral compound, code-named AVI-7. It worked differently from existing drugs: rather than targeting viral surface proteins (which mutate rapidly), AVI-7 attached to a host cell protein that the virus needed to replicate. In theory, this made it “resistance-proof.” But theory was not evidence. Now came the hard part
The trial that followed was a masterclass in scientific caution and ethics. After 14 days, 18 people on placebo had
With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it.
Before any human received AVI-7, Elena’s team tested it on human lung cell cultures infected with Phoenix. The drug reduced viral load by 99.9 percent within 48 hours without harming the cells. Next, they used ferrets—the gold standard for flu research—because ferrets cough, sneeze, and develop fever similarly to humans. Treated ferrets recovered fully; untreated ones died or suffered severe pneumonia.
But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning.
Try the excellence with us!
